Eli Lilly Enters a ~$1.4B Licensing Agreement with Sangamo Therapeutics for its STAC-BBB Capsid
Shots:
- Sangamo has granted Eli Lilly global exclusive license of STAC-BBB for one initial CNS target, with an option to add up to 4 more targets upon payment of additional license fees, allowing IV delivery of Lilly’s genomic medicines for CNS diseases
- As per the deal, Lilly will handle R&D, regulatory activities, manufacturing, & global marketing of products from the alliance in exchange for $18M upfront license fee & ~$1.4B in additional target fees & milestones across 5 potential neurology targets, plus net sales-based tiered royalties, while Sangamo will handle STAC-BBB tech transfer
- STAC-BBB is a neurotropic AAV capsid that has depicted strong BBB penetration & effective neuronal transduction in nonhuman primates
Ref: Businesswire | Image: Eli Lilly & Sangamo
Related News:- Eli Lilly Reports P-II (ALPACA) Trial Data of Lepodisiran for Heart Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
